KRAS and cancer: These observations suggest that even the moderate degradation of KRAS G12D by TUS-007 could allow for dose-dependent degradation (Figure 5A), cell cycle suppression (Figure 5B), and dose-dependent apoptotic response (Figure 5C,D) in SW1990 cancer cells.